ClinicalTrials.gg
Status unknownNCT00470236DCISUpdated Mar 22, 2023

Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast

An interventional study of Standard WB fractionation and Shorter WB fractionation in Carcinoma, Ductal, Breast, sponsored by Trans Tasman Radiation Oncology Group. Status unknown at 120 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-22.

Sponsored by Trans Tasman Radiation Oncology Group · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,608
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Hypotheses:

  1. The addition of tumour bed boost after BCS in women with non-low risk DCIS reduces the risk of local recurrence (invasive or intraductal recurrence in the ipsilateral breast).
  2. The risk of local recurrence in the shorter fractionation arm is not worse than that for the standard fractionation arm.
  3. A molecular signature predictive of invasive recurrence of DCIS will be detectable and the molecular signature may eventually have clinical utility for therapy individualization.

Overall Objectives:

  1. To improve the outcome of women with non-low risk DCIS treated with breast conserving therapy.
  2. To individualize treatment selection for women with DCIS to achieve long term disease control with minimal toxicity.
Read the detailed description

Specific objectives:

  1. To evaluate time to local recurrence in women with DCIS treated with breast conserving surgery followed by:

    • whole breast RT alone versus whole breast RT plus tumour bed boost;
    • RT using the standard fractionation schedule versus the shorter schedule.
  2. To evaluate time to disease recurrence and overall survival in women with DCIS treated with breast conserving surgery followed by:

    • whole breast RT alone versus whole breast RT plus tumour bed boost;
    • RT using the standard fractionation schedule versus the shorter schedule.
  3. To compare the toxicity of:

    • whole breast RT alone versus whole breast RT plus tumour bed boost;
    • RT using the standard fractionation schedule versus the shorter schedule.
  4. To compare the cosmetic outcome of:

    • whole breast RT alone versus whole breast RT plus tumour bed boost;
    • RT using the standard fractionation schedule versus the shorter schedule.
  5. To identify a molecular signature predictive of invasive recurrence of DCIS to facilitate therapy individualization.
  6. To assess inter-relationship of biomarkers and relationship between biomarker expression and specific histopathologic features of DCIS.
  7. To evaluate the quality of life of women treated with:

    • whole breast RT alone versus whole breast RT plus tumour bed boost;
    • RT using the standard fractionation schedule versus the shorter schedule.
02

Conditions studied

  • Carcinoma, Ductal, Breast

Keywords

  • Ductal carcinoma in-situ
  • Breast conserving therapy
  • Whole breast radiation therapy
  • Tumour bed boost
  • Fractionation schedules
  • Completely excised non-low risk DCIS
03

In context

Carcinoma, Ductal, Breast

86 studies on the registry are indexed under Carcinoma, Ductal, Breast; 7 are open to participants now.

This study's enrollment of 1,608 is above the median of 92 across 69 interventional studies indexed under Carcinoma, Ductal, Breast.

Browse Carcinoma, Ductal, Breast studies →

Lead sponsor

Trans Tasman Radiation Oncology Group is the lead sponsor of 36 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must fulfill all of the following criteria for admission to study:

  • Women ≥ 18 years.
  • proven DCIS of the breast without an invasive component.
  • Bilateral mammograms performed within 6 months prior to randomization.
  • Clinically node-negative.
  • Treated by breast conserving surgery (primary excision or re-excision) with complete microscopic excision and clear radial margins of ≥1 mm* (*Patients with superficial or deep resection margin of \<1 mm are eligible if surgery has removed all of the intervening breast tissue from the subcutaneous tissue to the pectoralis fascia).
  • Women who are at high risk of local recurrence due to:

    • Age \< 50 years; OR
    • Age ≥ 50 years plus at least one of the following:

      • Symptomatic presentation
      • Palpable tumour
      • Multifocal disease
      • Microscopic tumour size ≥ 1.5 cm in maximum dimension
      • Intermediate or high nuclear grade
      • Central necrosis
      • Comedo histology
      • Radial* surgical resection margin \< 10 mm. (*Patients with superficial or deep resection margin of \< 10 mm are eligible if surgery has not removed all of the intervening breast tissue from the subcutaneous tissue to the pectoralis fascia.)
  • Assessed by surgeon and radiation oncologist to be suitable for breast conserving therapy including whole breast RT.
  • Ability to tolerate protocol treatment.
  • Protocol RT should preferably commence within 8 weeks but must commence no later than 12 weeks from the last surgical procedure.
  • performance status 0, 1 or 2.
  • Patient's > 5 years.
  • Availability for long-term follow-up.
  • Written .

Exclusion criteria

Exclusion Criteria:

Patients who fulfill any of the following criteria are not eligible for admission to study:

  • Multicentric disease or extensive microcalcifications that could not be completely excised by breast conserving surgery with radial margins of ≥1 mm*.

    *Patients with superficial and/or deep margin of \<1 mm are eligible if surgery has removed all of the intervening breast tissue from the subcutaneous tissue to the pectoralis fascia.

  • Presence of tumour cells in lymph nodes detected using H\&E or immunohistochemical examination (if lymph node or dissection has been performed).
  • Locally recurrent breast cancer.
  • Previous DCIS or invasive cancer of the contralateral breast.

    • Bilateral DCIS of the breasts
    • Synchronous invasive carcinoma of the contralateral breast
  • Other concurrent or previous except:

    • Non-melanomatous skin cancer;
    • Carcinoma in situ of the cervix or endometrium; and
    • Invasive carcinoma of the cervix, endometrium, colon, thyroid and melanoma treated at least five years prior to study admission without disease recurrence.
  • Serious non-malignant disease that precludes definitive surgical or radiation treatment (e.g., scleroderma, systemic lupus erythematosus, cardiovascular/pulmonary/renal disease).
  • performance status ≥ 3.
  • Women who are pregnant or lactating.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,608 participants (actual)

Study arms

  • Active comparator
    Arm 1 (Standard WB Fractionation)

    Whole Breast RT alone - Standard fractionation schedule (50GY/25 Fractions/35days)

    Radiation: Standard WB fractionation

  • Experimental
    Arm 2 (Shorter WB Fractionation)

    Whole Breast RT alone - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days)

    Radiation: Shorter WB fractionation

  • Active comparator
    Arm 3 (Standard WB fractionation+Boost)

    Whole Breast RT + tumor bed boost - Standard fractionation schedule (50 Gy/25 fractions/35 days; Boost 16 Gy/8 fractions/10 days)

    Radiation: Standard WB fractionation+Boost

  • Experimental
    Arm 4 (Shorter WB fractionation + Boost)

    Whole breast RT + tumour bed boost - Shorter fractionation schedule (42.5 Gy/16 fractions/22 days; Boost 16 Gy/8 fractions/10 days)

    Radiation: Shorter WB fractionation + Boost

Interventions

  • RadiationStandard WB fractionation

    A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).

    Also known as: Radiation

  • RadiationShorter WB fractionation

    A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).

    Also known as: Radiation

  • RadiationStandard WB fractionation+Boost

    Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight). Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week.

    Also known as: Radiation

  • RadiationShorter WB fractionation + Boost

    Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight). Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week.

    Also known as: Radiation

06

What researchers measure

Primary outcomes

  1. Time to local recurrence, measured from the date of randomization to the date of first evidence of local recurrence.

    Time frame: Main analysis after all patients have completed 5 years of follow-up. Updated analysis after 10 years of follow-up.

Secondary outcomes

  1. Overall survival

    Time frame: Measured from the date of randomization to the date of death from any cause. Main analysis of secondary outcomes after all patients have completed 5 years of follow-up. Updated analysis after 10 years of follow-up.

  2. Time to disease recurrence

    Time frame: Measured from the date of randomization to the date of first evidence of recurrent disease. Main analysis of secondary outcomes after all patients have completed 5 years of follow-up. Updated analysis after 10 years of follow-up.

  3. Cosmetic Outcome

    Time frame: Cosmetic assessment will take place at baseline, 12, 36 and 60 months post RT.

  4. Radiation toxicity

    Time frame: Assessed at baseline, last week of RT, 3, 6, and 12 months post RT and then yearly until year 10.

  5. Quality of Life change

    Time frame: Assessed at baseline, last week of RT, 6, 12, 24, 60 & 120 months post RT.

07

Study locations

120 sites
  • Campbelltown Hospital
    Campbelltown, New South Wales 2560, Australia
  • Nepean Cancer Care Centre
    Kingswood, New South Wales, Australia
  • St George Hospital
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital
    Liverpool, New South Wales 2170, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Riverina Cancer Care Centre
    Wagga Wagga, New South Wales 2650, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Westmead Hospital
    Wentworthville, New South Wales 2145, Australia
  • Premion - Wesley
    Auchenflower, Queensland 4006, Australia
  • Royal Brisbane and Women's Hospital
    Brisbane, Queensland 4006, Australia
  • Princess Alexandra Hospital
    Brisbane, Queensland 4102, Australia
  • Genesis Cancer Care (previously Premion) - Nambour
    Nambour, Queensland, Australia
  • Radiation Oncology - Mater Centre
    South Brisbane, Queensland 4101, Australia
  • Toowoomba Cancer Research Centre
    Toowoomba, Queensland, Australia
  • North Queensland Oncology Service
    Townsville, Queensland 4810, Australia
  • Genesis Cancer Care (previously Premion) - Tugun
    Tugun, Queensland 4224, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • Launceston General Hospital
    Launceston, Tasmania 7250, Australia
  • Barwon Health - Andrew Love Cancer Care Centre, Geelong Hospital
    Geelong, Victoria 3220, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3002, Australia
  • Austin Hospital
    Melbourne, Victoria 3084, Australia
  • William Buckland Radiotherapy Centre, Alfred Hospital
    Melbourne, Victoria 3181, Australia
  • Sir Charles Gardiner Hospital
    Nedlands, Western Australia 6009, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6001, Australia
  • Perth Radiation Oncology
    Perth, Western Australia, Australia
  • Onze Lieve Vrouw Ziekenhuis
    Aalst, Belgium
  • ZNA Middelheim
    Antwerpen, Belgium
  • Cliniques Univeritaires St Luc
    Brussel, Belgium
  • Universitair Zielenhusi
    Brussel, Belgium
  • Hopital De Jolimont
    Haine St Paul, Belgium
  • AZ Groeninghe - Campus Maria's Voorzienigheid
    Kortrijk, Belgium
  • Algemeen Ziekenhis Sint-Augustinus
    Wilrijk, Belgium
  • Nova Scotia Cancer Centre
    Halifax, Canada
  • Jurvanski Cancer Centre
    Hamilton, Canada
  • Notre Dame Hospital
    Hearst, Canada
  • BCCA Southern Interior - CAVK
    Kelowna, Canada
  • London Regional Cancer Program
    London, Canada
  • Saint John Regional Hospital
    Miramichi, Canada
  • Leon Richard Oncology Centre
    Moncton, Canada
  • Hospital Maisonneuve-Rosemont
    Montreal, Canada
  • Lakeridge Health
    Oshawa, Canada
  • CHUQ L'Hotel-Dieu de Quebec
    Quebec, Canada
  • McGill University Department of Oncology
    Sainte-Anne-de-Bellevue, Canada
  • Allan Blair Cancer Centre
    Saskatoon, Canada
  • Saskatoon Cancer Centre
    Saskatoon, Canada
  • Universite de Sherbrooke - CUGH
    Sherbrooke, Canada
  • Thunder Bay Regional Health Sciences Centre
    Thunder Bay, Canada
  • Odette Cancer Centre
    Toronto, Canada
  • Princess Margaret Hospital
    Toronto, Canada
  • BCCA Vancouver Centre
    Victoria, Canada
  • Vancouver Island Cancer Centre
    Victoria, Canada
  • Cancer Care Manitoba
    Winnipeg, Canada
  • Chr De Grenoble - La Tronche
    Grenoble, France
  • Centre Antine Lacassagne
    Nice, France
  • Cork University Hospital
    Cork, Ireland
  • University Hospital Galway
    Galway, Ireland
  • SLRON (St Luke's Rad Onc Network)
    Rathgar, Ireland
  • Centro Di Riferimento Oncologico - Aviano
    Aviano, Italy
  • Fondazione Salvatore Maugeri
    Pavia, Italy
  • Academisch Medisch Centrum
    Amsterdam,, Netherlands
  • Cancer Institute Antoni Van Leeuwenhoekziekenhuis
    Amsterdam, Netherlands
  • Arnhem 'S Radiotherapeutisch Instituut
    Arnhem, Netherlands
  • Reinier de Graaf Groep
    Delft, Netherlands
  • University Medical Centre Groningen
    Groningen, Netherlands
  • Leiden University Medical Centre
    Leiden, Netherlands
  • Maastricht Radiation Oncology Maastro Clinic
    Maastricht, Netherlands
  • Medisch Centrum Haaglanden
    Westeinde, Netherlands
  • ISALA Klinieken
    Zwolle, Netherlands
  • Auckland Hospital
    Auckland, 1001, New Zealand
  • Christchurch Hospital
    Christchurch, 8011, New Zealand
  • Waikato Hospital
    Hamilton, 3204, New Zealand
  • National University Hospital
    Singapore, 119074, Singapore
  • University Hospital Basel
    Basel, Switzerland
  • IOSI
    Bellinzona, Switzerland
  • Inselspital Bern
    Bern, Switzerland
  • Kantonsspital Graubunden
    Chur, Switzerland
  • Kantonsspital Munsterlingen
    Munsterlingen, Switzerland
  • Kantonsspital St. Gallen
    St. Gallen, Switzerland
  • Brust-Zentrum Zurich-Seefeld
    Zurich, Switzerland
  • Klinik Hirslanden
    Zurich, Switzerland
  • Gloucestershire Royal & Cheltenham General Hospitals
    Cheltenham, Gloucestershire, United Kingdom
  • Churchill Hospital
    Oxford, Headington, United Kingdom
  • Pilgram Hospital
    Boston, Lincolnshire, United Kingdom
  • Mount Vernon Cancer Centre
    Northwood, Middlesex, United Kingdom
  • Ealing Hospital
    Southall, Middlesex, United Kingdom
  • Kings Mill Hospital Nottingham
    Sutton-In-Ashfield, Nottinghamshire, United Kingdom
  • Musgrove Park Hospital
    Taunton, Somerset, United Kingdom
  • Queens Hospital Burton
    Burton-On-Trent, Staffordshire, United Kingdom
  • University of North Staffordshire
    Stoke-On-Trent, Staffordshire, United Kingdom
  • Aberdeen Royal Infirmary
    Aberdeen, United Kingdom
  • Basildon University Hospital
    Basildon, United Kingdom
  • Belfast City Hospital
    Belfast, United Kingdom
  • Queen Elizabeth Hospital
    Birmingham, United Kingdom
  • Sandwell and West Birmingham Hospitals NHS Trust
    Birmingham, United Kingdom
  • Bristol Haematology & Oncology
    Bristol, United Kingdom
  • Colchester Hospital
    Colchester, United Kingdom
  • Coventry Arden Cancer Centre
    Coventry, United Kingdom
  • Royal Derby Hospital
    Derby, United Kingdom
  • Dumfries & Galloway Royal Infirmary
    Dumfries, United Kingdom

Showing the first 100 of 120 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA; BIG 3-07/TROG 07.01 trial investigators. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet. 2022 Aug 6;400(10350):431-440. doi: 10.1016/S0140-6736(22)01246-6. PubMed 35934006 ↗
  • King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH; BIG 3-07/TROG 07.01 trial investigators. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2020 May;21(5):685-698. doi: 10.1016/S1470-2045(20)30085-1. Epub 2020 Mar 20. PubMed 32203696 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jun 2024 and a completion of Jun 2024. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2007
First posted
May 7, 2007
Start
Jun 2007
Primary completionEst.
Jun 2024
CompletionEst.
Jun 2024
Last update
Mar 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00470236
Lead sponsor
Trans Tasman Radiation Oncology Group
Collaborators
Breast International Group, NCIC Clinical Trials Group, Cancer Trials Ireland, Borstkanker Onderzoek Groep, ETOP IBCSG Partners Foundation, Scottish Cancer Trials Breast Group, European Organisation for Research and Treatment of Cancer - EORTC
Responsible party
Sponsor
First posted
May 7, 2007
Start date
Jun 2007
Primary completion
Jun 2024 (estimated)
Completion
Jun 2024 (estimated)
Last update
Mar 22, 2023

Study contacts

Boon Chua
study chair · Prince of Wales Hospital Randwick

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion